Clinical and Economic Benefit of Advanced Therapies for the Treatment of Active Ankylosing Spondylitis

INTRODUCTION: Recent changes to treatment guidelines for ankylosing spondylitis (AS) have listed first-line advanced therapies as tumor necrosis factor (TNF), interleukin (IL)-17, and Janus kinase (JAK) inhibitors. This study sought to assess the comparative clinical and economic benefit of advanced...

Descripción completa

Detalles Bibliográficos
Autores principales: Walsh, Jessica A., Saffore, Christopher D., Collins, Eric B., Ostor, Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10468449/
https://www.ncbi.nlm.nih.gov/pubmed/37568031
http://dx.doi.org/10.1007/s40744-023-00586-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10468449/
https://www.ncbi.nlm.nih.gov/pubmed/37568031
http://dx.doi.org/10.1007/s40744-023-00586-6

Ejemplares similares